Dr Amit Patel is the first person in the UK qualified in stem cell transplantation/cellular therapy and intensive care medicine.
He graduated in Medicine from Imperial College London. After developing gene editing expertise at the Medical Research Council (MRC) London Research Institute he was awarded a PhD in Clinical Science and Molecular Genetics. He completed National Institute for Health Research (NIHR) and Academy of Medical Sciences funded postdoctoral research at the Institute of Cancer Research, and clinical academic training in London, mainly at the Royal Marsden and Hammersmith Hospitals. He was a Consultant Haematologist at the Clatterbridge Cancer Centre in Liverpool, before commencing his current Consultant role at The Christie NHS Foundation Trust.
He is currently the Lead Haematologist for the immune effector cell (IEC) therapy service that includes chimeric antigen receptor T cell (CAR-T) therapy at The Christie. He is also the Lead Clinician for Haematology and Transplant Research. Dr Patel is the current and previous UK Chief Investigator (CI) for national and international clinical trials, and principal investigator (PI) for clinical trials, including for CAR-T cell therapy. His significant research contribution has been nationally recognised, and in 2019 he won the Royal College of Physicians (RCP) NIHR Clinical Research Network (CRN) Joint Research Award.
During his tenure as Programme Director of Clatterbridge’s Stem Cell Transplantation and Cellular Therapy Unit, Dr Patel achieved step change improvement in patient survival outcomes to amongst the best in the UK. He was also the Lead Clinician for the Leukaemia Unit, where he similarly improved patient outcomes and access to innovative treatments for patients with ALL and AML. In addition, he was the Lead Clinician for Clinical Trials, both departmental within the NHS Trust, and regionally for the NIHR CRN North West Coast (NWC). His leadership achievements were recognised by the NWC Research and Innovation Awards 2020.
Dr Patel has developed regional patient pathways, as Chair of the Haematology Clinical Quality Group (CQG), within the Cheshire and Merseyside Cancer Alliance. This has reduced variation in both patient access and care.
He has delivered invited lectures at international and national meetings and conferences, published in high impact journals, contributed to patient support groups and charities including as a trustee, and provided clinical expertise and leadership to new and emerging therapies to accelerate patient access, including through NICE.